Jiangxi Shimei Pharmaceutical Co., Ltd.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation memantine hydrochloride orodisintegrating tablets (specification: 20 mg, produced by Jiangxi Shimei Pharmaceutical Co., Ltd.) and the reference preparation memantine hydrochloride orodisintegrating tablets (trade name: Memary; specification: 20 mg, produced by Daiichi Sankyo Co., Ltd.) in healthy Chinese adult subjects in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study: to evaluate the safety of the test preparation memantine hydrochloride orodisintegrating tablets and the reference preparation Memary in healthy Chinese adult subjects.

The main purpose of the study is to examine the pharmacokinetic parameters of the test preparation and the reference preparation in the fasting or postprandial state in healthy subjects by taking a single oral dose of the test preparation Sacubitril-Valsartan Sodium Tablets (Specification: 200 mg based on Sacubitril-Valsartan) produced by Jiangxi Shimei Pharmaceutical Co., Ltd. or the reference preparation Sacubitril-Valsartan Sodium Tablets (trade name: Nuxintu; Specification: 200 mg based on Sacubitril-Valsartan) produced by Novartis Singapore Pharmaceutical Manufacturing Private Ltd., respectively, and evaluate the bioequivalence of the two preparations. The secondary purpose of the study is to examine the safety of the test preparation and the reference preparation in healthy subjects.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation oseltamivir phosphate granules (specification: 0.9g (calculated as C16H28N2O4), produced by Jiangxi Shimei Pharmaceutical Co., Ltd.) and the reference preparation oseltamivir phosphate dry syrup (trade name: Tamiflu; specification: 3% (30mg/g, 30g), certified by Chugai Pharmaceutical Co., Ltd.) in healthy adult Chinese subjects when taken orally in the fasting/fed state, and to evaluate the bioequivalence of the two preparations when taken orally in the fasting/fed state. Secondary study objective: To evaluate the safety of the test formulation oseltamivir phosphate granules and the reference formulation Tamiflu in healthy adult subjects in China.